470 related articles for article (PubMed ID: 18503979)
1. GVHD pathophysiology: is acute different from chronic?
Toubai T; Sun Y; Reddy P
Best Pract Res Clin Haematol; 2008 Jun; 21(2):101-17. PubMed ID: 18503979
[TBL] [Abstract][Full Text] [Related]
2. Life-threatening graft-vs-host disease.
Vargas-Díez E; García-Díez A; Marín A; Fernández-Herrera J
Clin Dermatol; 2005; 23(3):285-300. PubMed ID: 15896544
[TBL] [Abstract][Full Text] [Related]
3. Acute and chronic skin graft-versus-host disease--pathophysiological aspects.
Socié G; Peffault de Latour R; Bouziz JD; Rybojad M
Curr Probl Dermatol; 2012; 43():91-100. PubMed ID: 22377923
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiology of graft-versus-host disease.
Ferrara JL; Reddy P
Semin Hematol; 2006 Jan; 43(1):3-10. PubMed ID: 16412784
[TBL] [Abstract][Full Text] [Related]
5. Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies.
Zeiser R; Marks R; Bertz H; Finke J
Ann Hematol; 2004 Sep; 83(9):551-65. PubMed ID: 15449032
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
Tian Y; Deng YB; Huang YJ; Wang Y
Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
[TBL] [Abstract][Full Text] [Related]
7. The FcgammaRIIa-polymorphic site as a potential target for acute graft-versus-host disease in allogeneic stem cell transplantation.
van der Straaten HM; Fijnheer R; Nieuwenhuis HK; van de Winkel JG; Verdonck LF
Biol Blood Marrow Transplant; 2005 Mar; 11(3):206-12. PubMed ID: 15744239
[TBL] [Abstract][Full Text] [Related]
8. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management.
Couriel D; Caldera H; Champlin R; Komanduri K
Cancer; 2004 Nov; 101(9):1936-46. PubMed ID: 15372473
[TBL] [Abstract][Full Text] [Related]
9. Histological evaluation of acute mucocutaneous graft-versus-host disease in nonmyeloablative hematologic stem cell transplants with an observation predicting an increased risk of progression to chronic graft-versus-host disease.
Bridge AT; Nelson RP; Schwartz JE; Mirowski GW; Billings SD
Am J Dermatopathol; 2007 Feb; 29(1):1-6. PubMed ID: 17284954
[TBL] [Abstract][Full Text] [Related]
10. [Effect of donor CD4+CD25+ regulatory T cells on hematopoietic and immune reconstitution, GVHD and disease-free survival after allogeneic hematopoietic stem cell transplantation].
Yang K; Fan ZP; Liu QF; Zhang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Apr; 28(4):537-41. PubMed ID: 18495584
[TBL] [Abstract][Full Text] [Related]
11. The thymus in GVHD pathophysiology.
Krenger W; Holländer GA
Best Pract Res Clin Haematol; 2008 Jun; 21(2):119-28. PubMed ID: 18503980
[TBL] [Abstract][Full Text] [Related]
12. T cell immunity and graft-versus-host disease (GVHD).
Ichiki Y; Bowlus CL; Shimoda S; Ishibashi H; Vierling JM; Gershwin ME
Autoimmun Rev; 2006 Jan; 5(1):1-9. PubMed ID: 16338205
[TBL] [Abstract][Full Text] [Related]
13. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation.
Dander E; Balduzzi A; Zappa G; Lucchini G; Perseghin P; Andrè V; Todisco E; Rahal D; Migliavacca M; Longoni D; Solinas G; Villa A; Berti E; Mina PD; Parma M; Allavena P; Biagi E; Rovelli A; Biondi A; D'Amico G
Transplantation; 2009 Dec; 88(11):1261-72. PubMed ID: 19996925
[TBL] [Abstract][Full Text] [Related]
15. Biological advances in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Duran-Struuck R; Reddy P
Transplantation; 2008 Feb; 85(3):303-8. PubMed ID: 18301323
[TBL] [Abstract][Full Text] [Related]
16. Host-reactive CD8+ memory stem cells in graft-versus-host disease.
Zhang Y; Joe G; Hexner E; Zhu J; Emerson SG
Nat Med; 2005 Dec; 11(12):1299-305. PubMed ID: 16288282
[TBL] [Abstract][Full Text] [Related]
17. Regulatory T-cell suppression of CD8+ T-cell-mediated graft-versus-host reaction requires their presence during priming.
Wang XN; Haniffa MA; Holtick U; Collin MP; Jackson G; Hilkens CM; Holler E; Edinger M; Hoffmann P; Dickinson AM
Transplantation; 2009 Jul; 88(2):188-97. PubMed ID: 19623013
[TBL] [Abstract][Full Text] [Related]
18. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
[TBL] [Abstract][Full Text] [Related]
19. [Allogeneic hematopoietic stem cell transplantation from HLA one-locus-mismatched related donors].
Hyo R; Taguchi J; Kamijo A; Tanaka M; Hashimoto C; Kanamori H; Motomura S; Maruta A; Ishigatsubo Y
Gan To Kagaku Ryoho; 2009 Nov; 36(11):1845-9. PubMed ID: 19920386
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis and treatment of acute graft-versus-host disease.
Chao NJ; Chen BJ
Semin Hematol; 2006 Jan; 43(1):32-41. PubMed ID: 16412787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]